Die kardiovaskuläre Risikoreduktion – „Trumpfkarte“ in der Diabetestherapie

Auch 2017 waren kardiovaskuläre Sicherheits- und Endpunktstudien wesentliche Highlights des Kongresses der „American Diabetes Association“ (ADA) – im Fokus standen dabei unter anderem DEVOTE, CANVAS, LEADER, REMOVAL und ODYSSEY Diabetes. Denn will man die Prognose von Menschen mit Typ-2-Diabetes positiv beeinflussen, gilt es neben der Kontrolle der Blutzuckerwerte insbesondere das kardiovaskuläre Risiko der Patienten zu senken.

• Literatur

• 1 Marso SP, McGuire DR, Zinman B. et al. Efficacy and safety of degludec versus glargin in type 2 diabetes. N Engl J Med Jun 2017; DOI: 10.1056/NEJMoa1615692. [Epub ahead of print]
• 2 Siegmund T, Tentolouris N, Knudsen ST. et al. Switching to Insulin degludec reduces the risk of hypoglycemia in patients with T1DM in a real-world setting. ADA 2017; 1014
• 3 Seufert J, Fritsche A, Andersen H. et al. Switching to insulin glargine 300 U/mL (Gla-300) after failure of basal supported oral therapy (BOT) with other basal insulins in T2DM patients improved glycemic control with less nocturnal hypoglycemia (TOP-2). ADA 2017; 1023
• 4 Neal B, Perkovic V, Mahaffey KW. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med DOI: 10.1056/NEJMoa1611925.
• 5 Zinman B, Wanner C, Lachin JM. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-2128 . doi:10.1056/NEJMoa1504720
• 6 Cavender MA, Nordhammar A, Birkeland KI. et al. Hospitalization for heart failure and death in new users of SGLT2 inhibitors in patients with and without cardiovascular disease – CVD-REAL Study. ADA 2017; 377-OR
• 7 Marso SP, Daniels GH, Brown-Frandsen K. et al. Liraglutide and Cardiovascular Outcomes in Type-2-Diabetes. N Engl J Med 2016; 375: 311-322 doi: 10.1056/NEJMoa1603827
• 8 Pratley R. New Learnings from the results of the Liraglutide Effect and Action in Diabetes – Evaluation of Cardiovascular Outcome Results (LEADER) Trial – New Results: Cardiovascular Outcomes. Vortrag auf dem auf dem Kongress der American Diabetes Association (ADA) am 11.06.2016.
• 9 Zinman B, Marso SP, Christiansen E. et al. Severe hypoglycemia, cardiovascular outcomes, and death – the LEADER experience. ADA 2017; 359-OR
• 10 Petrie JR, Chaturvedi N, Ford I. et al. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2017; DOI: 10.1016/S2213-8587(17)30194-8. [Epub ahead of print]
• 11 Henry RR. Alirocumab versus usual care in type 2 diabetes with mixed dyslipidemia – ODYSSEY DM-DYSLIPIDEMIA-Study. Vortrag auf dem Kongress der American Diabetes Association (ADA) am 11.06.2016.
• 12 Leiter LA. Alirocumab and insulin-treated diabetes – insights from the ODYSSEY DM-INSULIN Study. Vortrag auf dem Kongress der American Diabetes Association (ADA) am 11.06.2016.